InspireMD (NSPR) Robust Sequential Revenue Growth
Post# of 52
Posted On: 01/06/2015 12:37:35 AM
Parkinson's disease is a widespread and progressive neurodegenerative disorder resulting in disabling motor impairment.
Nerve cells use a brain chemical called dopamine to help control muscle movement. With Parkinson's disease, the brain cells that make dopamine slowly die. With less and less dopamine, a person has less and less ability to regulate their movements, body and emotions.
The four primary symptoms of Parkinson’s disease are tremor, or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance and coordination.
While a range of medications and surgical interventions is available to treat some of the symptoms of Parkinson's disease, no therapy has been shown to either prevent or cure the disease.
Minerva Neurosciences, Inc. (NERV) reported that results from a Primomed (use of PRIMate MOdels to support translational MEDicine) non-human primate study showed that treatment with an analog of MIN-301, the company's investigational neuregulin-1 compound, resulted in improvements in a range of symptoms associated with Parkinson's disease in primates. The analog used in the Primomed study differs from NERV's MIN-301 by a single amino acid.
In the pre-clinical study, Parkinson's disease symptoms were induced in marmosets by a standard protocol using subcutaneous injections of MPTP neurotoxin. The non-human primate MPTP model used in the Primomed study is the only animal model of early Parkinson's that replicates the progressive development of symptoms alongside progressive neurodegeneration.
Previous research in rodent models of Parkinson's disease has shown that NERV's MIN-301 has the potential to restore motor function. Results from the Primomed study involving an analog of MIN-301 were consistent with these previous results.
Neuregulins play key roles in myelination, neuronal integrity and cognition-related signaling. Neuregulin-1 has been shown to have neurotrophic and neuroprotective effects on dopaminergic neurons
NERV is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases.
More about Minerva Neurosciences, Inc. (NERV) at www.minervaneurosciences.com
**
For the fourth quarter 2014, ended December 31, InspireMD, Inc. (NSPR) reported total revenues of $900,000, a greater than 200% increase sequentially, and cash and cash equivalents of approximately $6.3 million, compared to approximately $5 million reported in the previous quarter, reflecting net proceeds of $7.4 million from NSPR's registered direct offering in November 2014.
The recent shift in the strategic focus of NSPR outlined in November, as well as subsequent reductions in spending on headcount and clinical programs has improved the Company's near term financial outlook.
NSPR seeks to utilize its proprietary MGuard(TM) with MicroNet(TM) technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
More about InspireMD, Inc. (NSPR) at www.inspiremd.com
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of San Bernardino, California ( www.sanbernardino.crwe-pr.com ) to the CRWE Network.
San Bernardino, part of a larger region referred to as the Inland Empire, is located 65 miles east of Los Angeles, and 50 miles from the Pacific Ocean. It is the 18th largest city in California
The City of San Bernardino had an estimated population in 2013 (U.S. Census Bureau) of 213,708, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
Online video is gaining strength as a source for content marketing. Strategic plans are being developed for its division CRWE Tube ( www.crwetube.com ) to improve the potential future growth for the company.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
Nerve cells use a brain chemical called dopamine to help control muscle movement. With Parkinson's disease, the brain cells that make dopamine slowly die. With less and less dopamine, a person has less and less ability to regulate their movements, body and emotions.
The four primary symptoms of Parkinson’s disease are tremor, or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance and coordination.
While a range of medications and surgical interventions is available to treat some of the symptoms of Parkinson's disease, no therapy has been shown to either prevent or cure the disease.
Minerva Neurosciences, Inc. (NERV) reported that results from a Primomed (use of PRIMate MOdels to support translational MEDicine) non-human primate study showed that treatment with an analog of MIN-301, the company's investigational neuregulin-1 compound, resulted in improvements in a range of symptoms associated with Parkinson's disease in primates. The analog used in the Primomed study differs from NERV's MIN-301 by a single amino acid.
In the pre-clinical study, Parkinson's disease symptoms were induced in marmosets by a standard protocol using subcutaneous injections of MPTP neurotoxin. The non-human primate MPTP model used in the Primomed study is the only animal model of early Parkinson's that replicates the progressive development of symptoms alongside progressive neurodegeneration.
Previous research in rodent models of Parkinson's disease has shown that NERV's MIN-301 has the potential to restore motor function. Results from the Primomed study involving an analog of MIN-301 were consistent with these previous results.
Neuregulins play key roles in myelination, neuronal integrity and cognition-related signaling. Neuregulin-1 has been shown to have neurotrophic and neuroprotective effects on dopaminergic neurons
NERV is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases.
More about Minerva Neurosciences, Inc. (NERV) at www.minervaneurosciences.com
**
For the fourth quarter 2014, ended December 31, InspireMD, Inc. (NSPR) reported total revenues of $900,000, a greater than 200% increase sequentially, and cash and cash equivalents of approximately $6.3 million, compared to approximately $5 million reported in the previous quarter, reflecting net proceeds of $7.4 million from NSPR's registered direct offering in November 2014.
The recent shift in the strategic focus of NSPR outlined in November, as well as subsequent reductions in spending on headcount and clinical programs has improved the Company's near term financial outlook.
NSPR seeks to utilize its proprietary MGuard(TM) with MicroNet(TM) technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
More about InspireMD, Inc. (NSPR) at www.inspiremd.com
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of San Bernardino, California ( www.sanbernardino.crwe-pr.com ) to the CRWE Network.
San Bernardino, part of a larger region referred to as the Inland Empire, is located 65 miles east of Los Angeles, and 50 miles from the Pacific Ocean. It is the 18th largest city in California
The City of San Bernardino had an estimated population in 2013 (U.S. Census Bureau) of 213,708, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
Online video is gaining strength as a source for content marketing. Strategic plans are being developed for its division CRWE Tube ( www.crwetube.com ) to improve the potential future growth for the company.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
(0)
(0)